BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: Therapeutic potential for APL

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 7, 2013, Pages 1115-1125

  Bashash, Davood ^a,b   Ghaffari, Seyed H ^a   Zaker, Farhad ^c   Kazerani, Maryam ^c   Hezave, Kebria ^c   Hassani, Saeed ^c   Rostami, Masomeh ^a   Alimoghaddam, Kamran ^a   Ghavamzadeh, Ardeshir ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute promyelocytic leukemia; Apoptosis; Arsenic trioxide; BIBR 1532; Combination therapy; Telomerase

Indexed keywords

ARSENIC TRIOXIDE; BIBR 1532; CASPASE 3; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; DRUG DOSE REDUCTION; FLOW CYTOMETRY; GENE REPRESSION; HUMAN; HUMAN CELL; METABOLISM; NUCLEOTIDE SEQUENCE; PROMYELOCYTIC LEUKEMIA; REAL TIME POLYMERASE CHAIN REACTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; UPREGULATION;

AMINOBENZOATES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARSENICALS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NAPHTHALENES; OXIDES; TELOMERASE;

EID: 84882801252     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990126     Document Type: Article

References (25)

1. Ghavamzadeh, A.; Alimoghaddam, K.; Ghaffari, S.H.; Rostami, S.; Jahani, M.; Hosseini, R.; Mossavi, A.; Baybordi, E.; Khodabadeh, A.; Iravani, M.; Bahar, B.; Mortazavi, Y.; Totonchi, M.; Aghdami, N. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol, 2006, 17, (1), 131-134.
2. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100, (1), 57-70.
3. Blackburn, E.H.; Greider, C.W.; Szostak, J.W. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med, 2006, 12, (10), 1133-1138.
4. Ghaffari, S.H.; Shayan-Asl, N.; Jamialahmadi, A.H.; Alimoghaddam, K.; Ghavamzadeh, A. Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. Ann Oncol, 2008, 19, (11), 1927-1934.
5. Damm, K.; Hemmann, U.; Garin-Chesa, P.; Hauel, N.; Kauffmann, I.; Priepke, H.; Niestroj, C.; Daiber, C.; Enenkel, B.; Guilliard, B.; Lauritsch, I.; Muller, E.; Pascolo, E.; Sauter, G.; Pantic, M.; Martens, U.M.; Wenz, C.; Lingner, J.; Kraut, N.; Rettig, W.J.; Schnapp, A. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J, 2001, 20, (24), 6958-6968.
6. Bashash, D.; Ghaffari, S.H.; Zaker, F.; Hezave, K.; Kazerani, M.; Ghavamzadeh, A.; Alimoghaddam, K.; Mosavi, S.A.; Gharehbaghian, A.; Vossough, P. Direct short-term cytotoxic effects of BIBR 1532 on acute promyelocytic leukemia cells through induction of p21 coupled with downregulation of c-Myc and hTERT transcription. Cancer Invest, 2012, 30, (1), 57-64.
7. Bashash, D.; Ghaffari, S.H.; Mirzaee, R.; Alimoghaddam, K.; Ghavamzadeh, A. Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells. Leuk Lymphoma, 2013, 54, (3), 561-568.
8. Jing, Y.; Dai, J.; Chalmers-Redman, R.M.; Tatton, W.G.; Waxman, S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood, 1999, 94, (6), 2102-2111.
9. Huang, X.J.; Wiernik, P.H.; Klein, R.S.; Gallagher, R.E. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol, 1999, 16, (1), 58-64.
10. Li, Y.M.; Broome, J.D. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res, 1999, 59, (4), 776-780.
11. Ghaffari, S.H.; Momeny, M.; Bashash, D.; Mirzaei, R.; Ghavamzadeh, A.; Alimoghaddam, K. Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkbeta-dependent induction of hTERT due to down-regulation of Pin1 transcription. Hematology, 2012, 17, (4), 198-206.
12. Zhao, L.; Wientjes, M.G.; Au, J.L. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res, 2004, 10, (23), 7994-8004.
13. Belloc, F.; Dumain, P.; Boisseau, M.R.; Jalloustre, C.; Reiffers, J.; Bernard, P.; Lacombe, F. A flow cytometric method using Hoechst 33342 and propidium iodide for simultaneous cell cycle analysis and apoptosis determination in unfixed cells. Cytometry, 1994, 17, (1), 59-65.
14. Momeny, M.; Zakidizaji, M.; Ghasemi, R.; Dehpour, A.R.; Rahimi- Balaei, M.; Abdolazimi, Y.; Ghavamzadeh, A.; Alimoghaddam, K.; Ghaffari, S.H. Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol, 2010, 27, (3), 833-842.
15. Beitzinger, M.; Oswald, C.; Beinoraviciute-Kellner, R.; Stiewe, T. Regulation of telomerase activity by the p53 family member p73. Oncogene, 2006, 25, (6), 813-826.
16. Wang, Z.; Kyo, S.; Takakura, M.; Tanaka, M.; Yatabe, N.; Maida, Y.; Fujiwara, M.; Hayakawa, J.; Ohmichi, M.; Koike, K.; Inoue, M. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res, 2000, 60, (19), 5376-5381.
17. Henderson, Y.C.; Breau, R.L.; Liu, T.J.; Clayman, G.L. Telomerase activity in head and neck tumors after introduction of wild-type p53, p21, p16, and E2F-1 genes by means of recombinant adenovirus. Head Neck, 2000, 22, (4), 347-354.
18. John, K.; Alla, V.; Meier, C.; Putzer, B.M. GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria. Cell Death Differ, 2011, 18, (5), 874-886.
19. Melino, G.; Bernassola, F.; Ranalli, M.; Yee, K.; Zong, W.X.; Corazzari, M.; Knight, R.A.; Green, D.R.; Thompson, C.; Vousden, K.H. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem, 2004, 279, (9), 8076-8083.
20. Kang, K.H.; Kim, W.H.; Choi, K.H. p21 promotes ceramideinduced apoptosis and antagonizes the antideath effect of Bcl-2 in human hepatocarcinoma cells. Exp Cell Res, 1999, 253, (2), 403-412.
21. El Daly, H.; Martens, U.M. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small nonnucleosidic synthetic compounds (BIBR1532). Methods Mol Biol, 2007, 405, 47-60.
22. Ward, R.J.; Autexier, C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol, 2005, 68, (3), 779-786.
23. Meng, E.; Taylor, B.; Ray, A.; Shevde, L.A.; Rocconi, R.P. Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells. Gynecol Oncol, 2012, 124, (3), 598-605.
24. Tabori, U.; Wong, V.; Ma, J.; Shago, M.; Alon, N.; Rutka, J.; Bouffet, E.; Bartels, U.; Malkin, D.; Hawkins, C. Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma. Br J Cancer, 2008, 99, (7), 1129-1135.
25. Cazzalini, O.; Scovassi, A.I.; Savio, M.; Stivala, L.A.; Prosperi, E. Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat Res, 2010, 704, (1-3), 12-20.